Kliniske retningslinier for uroteliale tumorer i øvre urinveje

(51) Kojima Y, Tozawa K, Kawai N, Sasaki S, Hayashi Y, Kohri K. Long-term outcome of upper urinary
tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guerin
therapy. Int J Urol 2006 Apr;13(4):340-4.
(52) Giannarini G, Kessler TM, Birkhauser FD, Thalmann GN, Studer UE. Antegrade perfusion with
bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the
upper urinary tract: who may benefit? Eur Urol 2011 Nov;60(5):955-60.
(53) Lughezzani G, Sun M, Perrotte P, et al. Should bladder cuff excision remain the standard of
care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A
population-based study. Eur Urol 2010 Jun;57(6):956-62.
(54) Phe V, Cussenot O, Bitker MO, Roupret M. Does the surgical technique for management of the
distal ureter influence the outcome after nephroureterectomy? BJU Int 2011 Jul;108(1):130-8.
(55) Laguna MP, de la Rosette JJ. The endoscopic approach to the distal ureter in
nephroureterectomy for upper urinary tract tumor. J Urol 2001 Dec;166(6):2017-22.
(56) Walton TJ, Novara G, Matsumoto K, et al. Oncological outcomes after laparoscopic and open
radical nephroureterectomy: results from an international cohort. BJU Int 2011
Aug;108(3):406-12.
(57) Roscigno M, Shariat SF, Margulis V, et al. The extent of lymphadenectomy seems to be
associated with better survival in patients with nonmetastatic upper-tract urothelial
carcinoma: how many lymph nodes should be removed? Eur Urol 2009 Sep;56(3):512-8.
(58) Kondo T, Tanabe K. The role of lymph node dissection in the management of urothelial
carcinoma of the upper urinary tract. Int J Clin Oncol 2011 Jun;16(3):170-8.
(59) O'Brien T, Ray E, Singh R, Coker B, Beard R. Prevention of bladder tumours after
nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective,
multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C
(the ODMIT-C Trial). Eur Urol 2011 Oct;60(4):703-10.
(60) Koga F, Nagamatsu H, Ishimaru H, Mizuo T, Yoshida K. Risk factors for the development of
bladder transitional cell carcinoma following surgery for transitional cell carcinoma of the
upper urinary tract. Urol Int 2001;67(2):135-41.
(61) Chen B, Zeng ZC, Wang GM, et al. Radiotherapy may improve overall survival of patients with
T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour
relapse. BMC Cancer 2011;11:297.
(62) Vassilakopoulou M, de la Motte RT, Colin P, et al. Outcomes after adjuvant chemotherapy in
the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results
from a large multicenter collaborative study. Cancer 2011 Dec 15;117(24):5500-8.
(63) Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract
urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol
2009 Sep;182(3):900-6.